10-K: ProPhase Labs 2025 Annual Report: Bankruptcy and Pivot
Annual Report
ProPhase Labs reports a net loss of $14.7 million for 2025, following the Chapter 11 bankruptcy filing of its diagnostic subsidiaries and a strategic shift toward genomics and biotechnology.
Summary
- Net revenue for 2025 was $4.3 million, a 35.8% decrease from $6.8 million in 2024.
- The company reported a net loss of $14.7 million for 2025, compared to a $53.4 million loss in 2024.
- Diagnostic services revenue was zero for 2025 as the company ceased these operations.
- The company deconsolidated its diagnostic subsidiaries (PDX) following their Chapter 11 bankruptcy filing on September 22, 2025.
- The company sold its Pharmaloz Manufacturing, Inc. (PMI) business in January 2025, resulting in a gain of $8.7 million.
- As of December 31, 2025, the company had $90,000 in cash and a working capital deficit of $49.9 million.
- The company is focusing on its genomics business (Nebula Genomics, DNA Complete) and biotechnology (BE-Smart test, Linebacker compounds).
Sentiment
Score: 2
Explanation: StockSavvy.ai views this as a highly distressed situation characterized by bankruptcy, going concern warnings, and severe liquidity constraints.
Positives
- Successful sale of Pharmaloz Manufacturing, Inc. (PMI) resulted in a gain of $8.7 million and debt reduction.
- Gross margin improved to 31.9% in 2025 from a loss of 2.2% in 2024.
- General and administrative expenses decreased by $18.6 million compared to 2024.
- Issuance of a new patent for the BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test.
Negatives
- Significant liquidity constraints with only $90,000 in cash as of year-end.
- Substantial doubt regarding the company's ability to continue as a going concern.
- Diagnostic subsidiaries filed for Chapter 11 bankruptcy.
- Material weaknesses in internal control over financial reporting identified.
- Common stock is no longer listed on Nasdaq and trades on OTC Markets.
Risks
- Substantial doubt about the company's ability to continue as a going concern.
- Uncertainty regarding the outcome and timing of the Chapter 11 bankruptcy reorganization of diagnostic subsidiaries.
- Dependence on raising additional capital to fund operations.
- Legal risks associated with a pending qui tam complaint and a class action lawsuit against Nebula Genomics.
- Regulatory risks related to the development and commercialization of LDTs and pharmaceutical candidates.
Future Outlook
The company plans to focus on growing its genomics and biotechnology businesses, including the commercialization of the BE-Smart test and Linebacker compounds, while actively seeking additional capital and strategic alternatives to address liquidity needs.
Management Comments
- Management acknowledges substantial doubt regarding the company's ability to continue as a going concern.
- Management is actively evaluating alternatives to improve liquidity, including capital raises and strategic partnerships.
- The company is pursuing reorganization of its diagnostic subsidiaries to restore solvency.
Industry Context
StockSavvy.ai notes that ProPhase Labs is undergoing a painful transition from a COVID-19 testing-dependent model to a speculative biotech and genomics firm, a trend seen in many pandemic-era diagnostic companies struggling to find sustainable post-COVID revenue streams.
Comparison to Industry Standards
- The company's pivot to genomics and LDTs aligns with broader industry trends, but its liquidity position is significantly weaker than established competitors like Quest Diagnostics or LabCorp.
- The reliance on high-risk, early-stage biotech assets (Linebacker, BE-Smart) contrasts with the more diversified revenue bases of larger biotech peers.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Operating Officer | Jed A. Latkin | Stuart Hollenshead | 2025-02-17 | Inducement for employment |
| Chief Operating Officer | Stuart Hollenshead | N/A | 2025-07-31 | Resignation |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Reverse Stock Split | 1-for-10 reverse stock split effective December 2, 2025. | 2025-12-02 | Increased per-share trading price to meet listing requirements. |
| Authorized Shares Increase | Increased authorized common stock from 50 million to 1 billion shares. | 2025-09-15 | Provides capacity for future equity financing. |
Legal Proceedings
- A qui tam complaint alleging False Claims Act violations remains pending.
- A pending arbitration proceeding with Turnpoint Capital regarding a convertible note.
- A putative class action lawsuit (Portillo v. Nebula Genomics) regarding GIPA compliance.
Related Party Transactions
- Loan agreement with CEO Ted Karkus.
- Consulting services provided by 10PM Curfew, a company associated with former COO Stuart Hollenshead.
Stakeholder Impact
- Shareholders face significant dilution risk from potential capital raises and convertible debt.
- Creditors are impacted by the Chapter 11 bankruptcy of diagnostic subsidiaries.
- Employees face uncertainty due to the company's financial distress and restructuring.
Next Steps
- Continue reorganization of diagnostic subsidiaries under Chapter 11.
- Pursue commercialization of the BE-Smart test.
- Seek additional financing to support operations.
- Remediate material weaknesses in internal controls.
Key Dates
| Date | Description |
|---|---|
| 2025-01-16 | Sale of Pharmaloz Manufacturing, Inc. (PMI) completed. |
| 2025-09-22 | Diagnostic subsidiaries filed for Chapter 11 bankruptcy and were deconsolidated. |
| 2025-12-02 | 1-for-10 reverse stock split became effective. |
| 2026-06-01 | Date of the 10-K filing. |
Recommendation
sellThe company is in a state of financial distress with a going concern warning, bankruptcy of its primary revenue-generating segment, and extreme liquidity issues, making it a high-risk investment.
Keywords
ProPhase Labs, PRPH, Genomics, Biotech, Chapter 11, Nebula Genomics, BE-Smart, Diagnostic Testing, Going Concern
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.